Description

BRIMOTO Injection 50 mg/5 mL - Hospital IV - Intra Life

BRIMOTO Injection is a Schedule H prescription drug supplied as brivaracetam 50 mg/5 mL in a 5 mL single-dose vial. The pack facts supplied for this page state IV use only, storage below 30°C, protection from light, and do not freeze. These pack-stated details should be checked against the current physical pack and approved Indian label before procurement or administration.

Brivaracetam is an antiseizure medicine. A CDSCO approval record for brivaracetam injection 50 mg/5 mL describes the dosage form and route as an additional dosage form and new route of administration, with use as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy [3]. Because the official Intra Life product page for the injection currently displays website errors and does not provide reliable product particulars, this page does not assign a broader indication to BRIMOTO Injection. The treating prescriber must confirm the locally approved indication, age range, dose, and hospital protocol.

This page is educational and commercial information for healthcare professionals and legitimate pharmaceutical trade enquiries. It does not diagnose, prescribe, replace the package insert, or make a claim for emergency seizure treatment or status epilepticus. Do not use this page to select a dose for an individual patient.

Product facts

Appropriate use and therapeutic role

The locally supportable role identified in the CDSCO record is adjunctive therapy for partial-onset seizures in patients 16 years of age and older with epilepsy [3]. In practical terms, the injectable presentation may be considered by a prescriber when a patient who is otherwise a candidate for brivaracetam cannot temporarily take an oral formulation. The FDA label for the reference product states that injection is used when oral administration is temporarily not feasible and that the injectable form follows the same dose and frequency as the oral regimen . The Indian approved label for BRIMOTO Injection remains controlling.

Do not present BRIMOTO Injection as a cure for epilepsy. Do not describe it as universally suitable for every seizure, as a guaranteed rescue medicine, or as an approved treatment for status epilepticus unless the current Indian label specifically supports that claim. Seizures require clinical assessment, monitoring, and treatment according to institutional protocols.

How the component works

Brivaracetam is an antiseizure medicine in the racetam class. Class-level pharmacology describes selective binding to synaptic vesicle protein 2A (SV2A), a protein involved in the release of neurotransmitters from nerve terminals. This is understood to help modulate excessive neuronal signalling. The mechanism is educational context, not a promise of response in an individual patient. The relevant product label and prescriber’s assessment determine whether and how it should be used.

Administration and device use

BRIMOTO Injection must be given only by the IV route and only by a qualified healthcare professional. It is not intended for home injection, self-administration, or use with an unapproved device. The prescriber and hospital pharmacist should verify the current Indian label for preparation, compatibility, dilution, infusion duration, dose, frequency, patient age, hepatic considerations, and monitoring.

The FDA reference label describes IV administration over 2–15 minutes and permits administration without further dilution or mixing with specified diluents, but those details must not be transferred automatically to BRIMOTO Injection . Use only the diluent, line, syringe, infusion device, aseptic technique, and administration rate permitted by the approved Indian label and hospital policy. Inspect the vial and solution where the label permits; do not use a container with visible particulate matter, unexpected colour change, damage, or compromised integrity. A single-dose vial is for one use only; discard unused contents in accordance with institutional procedures.

Do not calculate or alter a dose from this page. Confirm the prescription, patient identity, strength, expiry, route, and label instructions before administration. If oral therapy is temporarily feasible again, the treating clinician should decide any transition. Antiseizure medicines should not be stopped abruptly without prescriber direction.

Important safety information and common adverse effects

Do not use brivaracetam in a patient with a known hypersensitivity to brivaracetam or any ingredient listed in the approved product information. The prescriber should review liver disease, pregnancy or breastfeeding, mental-health history, substance-use history, allergies, and all prescription, over-the-counter, herbal, and nutritional products before treatment. Reference labels warn about somnolence, fatigue, dizziness, impaired coordination, psychiatric or behavioural changes, suicidal thoughts or behaviour, and hypersensitivity reactions including bronchospasm and angioedema .

Commonly reported effects in reference product information include drowsiness or somnolence, dizziness, fatigue, nausea, vomiting, constipation, irritability, anxiety, and injection-site discomfort . Individual risk varies. Alcohol may worsen impairment; patients should follow their clinician’s advice. Patients should not drive or operate machinery until they know how the medicine affects alertness and coordination.

Seek urgent medical attention for breathing or swallowing difficulty, facial or throat swelling, widespread rash, blistering or peeling skin, severe behavioural or psychiatric changes, or suicidal thoughts. Report suspected adverse reactions through the applicable Indian pharmacovigilance pathway and inform the treating healthcare professional. This page does not provide emergency instructions; follow local emergency protocols.

Storage and handling

Store BRIMOTO Injection below 30°C, protect from light, and do not freeze, as stated in the supplied pack facts. Keep the vial in its original packaging where appropriate. Do not use it after the expiry date or if the container is damaged. Confirm any in-use, diluted-solution, transport, or excursion requirement in the approved Indian label and hospital pharmacy procedure. Keep prescription medicines controlled and accessible only to authorised personnel.

PCD franchise and distributor opportunities

Intra Life’s official website presents a PCD pharma franchise model with city-wise opportunities, product supply, marketing and promotional support, and enquiry routes for distributors, wholesalers, chemists, hospitals, and franchise partners . The website reports a broad portfolio that includes injections and speciality ranges, and states that partners may receive product training, marketing materials, order support, and logistics assistance . Availability of BRIMOTO Injection, territory rights, minimum order quantity, commercial terms, credit, margins, and supply schedule are not guaranteed on this page and must be confirmed in writing.

A prospective PCD or distribution partner should provide its legal entity details, drug licence information, GST details, operating territory, storage capability, and intended channel. Intra Life should confirm product availability, current approved labelling, batch-release documentation, cold-chain or temperature requirements if any, and applicable commercial terms before an order is placed. No page claim should be read as a guaranteed monopoly territory, profit, ranking, or sales outcome.

Third-party-manufacturing enquiries

For third-party manufacturing or contract supply, contact Intra Life for a product-specific feasibility review. The company website states that its range is manufactured in certified facilities and follows quality and regulatory controls at a company-level marketing description [1]. This does not independently verify the manufacturing site, licence, GMP status, technical agreement, batch-release responsibility, or availability of BRIMOTO Injection for third-party manufacture.

Any enquiry should request written confirmation of the manufacturing site, applicable manufacturing and wholesale licences, GMP and inspection status, product permission, approved artwork and label, stability and specification documentation, pharmacovigilance responsibilities, minimum batch size, lead time, and quality agreement. A contract should be signed only after regulatory, technical, and commercial due diligence. No claim of guaranteed registration, exclusivity, supply, or market success is made here.

Why partner with Intra Life?

Intra Life’s official homepage identifies the company as Intra Life Private Limited and lists corporate and branch contacts in Bengaluru, Ghaziabad, Kolkata, and a Bengaluru warehouse . The same homepage reports 46+ years of experience, 3,500+ pharma products, 2,200+ distributors nationwide, 1,000+ franchise partners, and PAN-India presence . These are company-level figures published by Intra Life and should be treated as self-reported corporate information, not as an independent audit or a product-specific performance guarantee.

The site also describes a portfolio spanning tablets, capsules, syrups, injections, paediatric medicines, nutraceuticals, antibiotics, and general medicines, alongside quality-assurance and partner-support statements . Partners should still evaluate the exact product dossier, licences, service levels, supply history, and written terms for BRIMOTO Injection before proceeding.

Frequently asked questions

1. What is BRIMOTO Injection?

BRIMOTO Injection is the supplied brand name for brivaracetam 50 mg/5 mL in a 5 mL single-dose vial. It is a Schedule H prescription drug for IV use only, according to the pack facts provided for this page.

2. What is the composition of BRIMOTO Injection?

The active component is brivaracetam 50 mg/5 mL. Excipients should be checked on the current approved label or pack; none are inferred here.

3. What is BRIMOTO Injection used for?

The CDSCO record supports adjunctive treatment of partial-onset seizures in patients 16 years and older with epilepsy . The prescriber must verify the current Indian indication before use.

4. Is it an emergency injection or a status-epilepticus medicine?

This page makes no such claim. Emergency or status-epilepticus use must not be inferred unless specifically supported by the current Indian approved label and clinical protocol.

5. Who can administer it?

Only a qualified healthcare professional in an appropriate clinical setting should administer it. It is not for self-administration or unsupervised home use.

6. Is BRIMOTO Injection IV or intramuscular?

The supplied pack facts state IV use only. Do not use it by another route unless the approved Indian label explicitly permits that route.

7. Can I choose the dose from this page?

No. Dose, frequency, infusion method, and any transition from oral therapy must be prescribed and checked against the approved Indian label and patient factors.

8. What are common adverse effects?

Reference information reports drowsiness, dizziness, fatigue, nausea, vomiting, constipation, mood or behavioural symptoms, and possible injection-site discomfort . Ask the treating clinician about the product-specific profile.

9. What important warnings apply?

Hypersensitivity, impaired alertness or coordination, psychiatric or behavioural changes, suicidal thoughts or behaviour, and interactions with other medicines require clinical attention . Do not stop treatment abruptly without prescriber guidance.

10. How should it be stored?

Store below 30°C, protect from light, and do not freeze, as stated on the supplied pack facts. Confirm excursion and in-use rules in the current label.

11. What is the pack size?

The supplied pack-confirmed presentation is one 5 mL single-dose vial. Confirm the marketed carton configuration with Intra Life before ordering.

12. What is the price of BRIMOTO Injection?

No price is published in this page. Price depends on channel, territory, taxes, quantity, and current commercial terms. Request a written quotation from Intra Life.

13. Is BRIMOTO Injection available for PCD franchise?

Availability and territory rights must be confirmed directly. Intra Life’s website describes city-wise PCD opportunities, but no specific BRIMOTO Injection allocation is guaranteed .

14. Can wholesalers or hospitals enquire?

Yes. Legitimate hospitals, distributors, wholesalers, chemists, and other authorised buyers may contact Intra Life for availability, documentation, and commercial terms.

15. Does Intra Life offer third-party manufacturing?

A product-specific third-party manufacturing enquiry may be submitted, but site, licence, GMP, dossier, batch size, and regulatory responsibilities must be verified in writing before any commitment.

Medical and B2B disclaimer : 

This page is not medical advice, a prescription, a diagnosis, or a substitute for the current approved Indian label, package insert, hospital formulary, or prescriber’s instructions. It is not intended to promote self-medication, off-label use, emergency use, status-epilepticus treatment, or a guaranteed outcome. Healthcare professionals must independently verify the product identity, batch, expiry, strength, route, compatibility, dose, patient suitability, and monitoring requirements.

B2B information is subject to written confirmation by Intra Life. Territory, monopoly rights, price, margin, supply, manufacturing, registration, delivery, product availability, and business performance are not guaranteed. Intra Life company figures and programme descriptions cited on this page are published on its official website and are not independent audit findings. The official BRIMOTO Injection URL currently returns server-side undefined-variable warnings and does not expose reliable product details; therefore, this page relies on the pack facts supplied in the brief and does not invent missing product claims.

Keywords